Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Other Operating Expenses (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Other Operating Expenses readings, the most recent being $750000.0 for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 30.89% to $750000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.9 million, a 11.81% decrease, with the full-year FY2025 number at $3.9 million, down 10.99% from a year prior.
  • Other Operating Expenses hit $750000.0 in Q4 2025 for Aligos Therapeutics, down from $1.1 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $1.6 million in Q1 2024 to a low of -$225000.0 in Q2 2021.
  • Median Other Operating Expenses over the past 5 years was $797500.0 (2022), compared with a mean of $677650.0.
  • Biggest five-year swings in Other Operating Expenses: plummeted 104.5% in 2022 and later skyrocketed 20140.0% in 2023.
  • Aligos Therapeutics' Other Operating Expenses stood at $176000.0 in 2021, then skyrocketed by 380.11% to $845000.0 in 2022, then crashed by 71.12% to $244000.0 in 2023, then soared by 134.84% to $573000.0 in 2024, then skyrocketed by 30.89% to $750000.0 in 2025.
  • The last three reported values for Other Operating Expenses were $750000.0 (Q4 2025), $1.1 million (Q3 2025), and $1.2 million (Q2 2025) per Business Quant data.